ISCTM 2022: Scientific Posters Compilation September 19, 2022 Signant Health Posted in Scientific Advisory Share: LinkedInTweet Signant’s neuroscience team and CNS experts presented scientific posters at the 2022 Autumn Conference hosted by the International Society for CNS Clinical Trials and Methodology. The posters presented original research on a variety of topics related to the Positive and Negative Syndrome Scale (PANSS), including the potential impact of baseline PANSS symptom domain severity on interview duration and abnormal patterns of variability such as post-baseline 30/30 PANSS identical ratings. Separately, we examined whether a 10-item PANSS optimized for pediatric trials would perform similarly to the 30-item PANSS in an independent placebo-controlled multi-site trial. Other posters delved into research on the Mini-Mental State Exam (MMSE) for dementia, including the association between the MMSE interview duration and the presence of administration and/or scoring errors, and the impact of the number of per rater MMSE administrations on the probability of identifying an administration or scoring MMSE error. Browse through each poster below and meet our experts to learn how Signant has been optimizing CNS clinical research for over 20 years. The Impact of Baseline PANSS Factor Scores on the Incidence of Post-Baseline Identical Ratings Exploring the Impact of MMSE Assessment Duration on Scoring and Administration Errors Optimized 10 Item PANSS for Pediatric Trials: Comparison to 30 Item Version in a Multi-Site Trial for Adolescent Schizophrenia The Impact of Number of Prior In-Study MMSE Administrations on the Presence of MMSE Scoring or Administration Errors in Dementia Clinical Trials Does Baseline Symptom Domain Severity Predict Interview Duration in Acute Schizophrenia Clinical Trials? An Exploratory Retrospective Analysis Signant Health facebook twitter google-plus linkedin Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently generate quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 20 years, over 400 sponsors and CROs of all sizes – including all of Top 20 pharma – have trusted Signant Health solutions for remote and site-based eCOA, eConsent, IRT, supply chain management, and data quality analytics. Recent Posts Data Analytics Clinical Trial Data: Navigating Audit Trail Data Regulations and Accessibility Challenges Apr 18, 2024 James Stringer Learn more eCOA Webinar Recap: Unleashing the Power of PROs Throughout Oncology Drug Development Feb 28, 2024 Signant Health Learn more eCOA 7 eCOA Solution Design Recommendations: Applied Insights from Trial Sites and CRAs Feb 12, 2024 Katie Garner Learn more General 5 Top Clinical Research Themes and Trends of 2023 (and 2024) Jan 02, 2024 Signant Health Learn more eCOA Webinar Recap: How EDC Can Support Modern Clinical Trials Dec 08, 2023 Signant Health Learn more
Signant’s neuroscience team and CNS experts presented scientific posters at the 2022 Autumn Conference hosted by the International Society for CNS Clinical Trials and Methodology. The posters presented original research on a variety of topics related to the Positive and Negative Syndrome Scale (PANSS), including the potential impact of baseline PANSS symptom domain severity on interview duration and abnormal patterns of variability such as post-baseline 30/30 PANSS identical ratings. Separately, we examined whether a 10-item PANSS optimized for pediatric trials would perform similarly to the 30-item PANSS in an independent placebo-controlled multi-site trial. Other posters delved into research on the Mini-Mental State Exam (MMSE) for dementia, including the association between the MMSE interview duration and the presence of administration and/or scoring errors, and the impact of the number of per rater MMSE administrations on the probability of identifying an administration or scoring MMSE error. Browse through each poster below and meet our experts to learn how Signant has been optimizing CNS clinical research for over 20 years. The Impact of Baseline PANSS Factor Scores on the Incidence of Post-Baseline Identical Ratings Exploring the Impact of MMSE Assessment Duration on Scoring and Administration Errors Optimized 10 Item PANSS for Pediatric Trials: Comparison to 30 Item Version in a Multi-Site Trial for Adolescent Schizophrenia The Impact of Number of Prior In-Study MMSE Administrations on the Presence of MMSE Scoring or Administration Errors in Dementia Clinical Trials Does Baseline Symptom Domain Severity Predict Interview Duration in Acute Schizophrenia Clinical Trials? An Exploratory Retrospective Analysis Signant Health facebook twitter google-plus linkedin Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently generate quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 20 years, over 400 sponsors and CROs of all sizes – including all of Top 20 pharma – have trusted Signant Health solutions for remote and site-based eCOA, eConsent, IRT, supply chain management, and data quality analytics.